Regeneron Stock Sinks on Disappointing Sales of Eylea Treatment

Regeneron Pharmaceuticals


stock was tumbling after the medicine maker reported lower sales of its Eylea treatment than Wall Street was anticipating for the fourth quarter.

In a preliminary update on its fourth quarter on Monday,


Regeneron


(ticker: REGN) said fourth-quarter sales of Eylea were $1.5 billion. The consensus call among analysts tracked by FactSet was for $1.64 billion, while the year-earlier figure was $1.55 billion.